Nöroimmünolojik Hastalıkların Ortaya Çıkış Mekanizmaları
Özet
İmmün sistemin kendi dokularına karşı geliştirdiği toleransın genetik veya çevresel faktörlerle bozulması, otoimmün hastalıkların temel tetikleyicisidir. Multipl Skleroz gibi nöroimmunolojik durumlarda, T ve B hücrelerinin merkezi sinir sistemine sızması inflamasyon, demiyelinizasyon ve aksonal hasara yol açarak klinik tabloyu oluşturmaktadır. Çocukluk çağı antikor ilişkili demiyelinizan hastalıklarda ise MOG ve AQP4 gibi antikorlar, erişkinlerden farklı immünolojik süreçlerle patogenezde aktif rol oynamaktadır. Bu karmaşık hastalık süreçlerinin ve epitop yayılımı gibi mekanizmaların aydınlatılması, gelecekteki tedavi modalitelerinin başarısı için kritik öneme sahiptir.
The failure of immune system self-tolerance mechanisms, driven by genetic and environmental triggers, serves as the primary catalyst for autoimmune disease development. In neuroimmunological conditions like Multiple Sclerosis, the infiltration of T and B cells into the central nervous system results in significant inflammation, demyelination, and axonal damage. Pediatric antibody-associated demyelinating diseases feature distinct pathogenesis, where antibodies such as MOG and AQP4 play specialized roles compared to adult presentations. Advancing future therapeutic strategies relies heavily on deepening the current understanding of these underlying molecular pathways and immunological processes.
Referanslar
Davidson A, Diamond B. Autoimmune diseases. N Engl J Med 2001;345:340-350.
Rose NR. Autoimmune diseases: tracing the shared threads. Hosp Pract (1995) 1997;32:147-154.
Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 1997;84:223-243.
Eaton WW, Rose NR, Kalaydjian A, Pedersen MG, Mortensen PB. Epidemiology of autoimmune diseases in Denmark. J Autoimmun 2007;29:1-9.
Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: a comprehensive update. J Intern Med 2015;278:369-395.
Bolon B. Cellular and molecular mechanisms of autoimmune disease. Toxicol Pathol 2012;40:216-229.
Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-1517.
Alroughani R, Boyko A. Pediatric multiple sclerosis: a review. BMC Neurol 2018;18:27.
Popescu BF, Pirko I, Lucchinetti CF. Pathology of multiple sclerosis: where do we stand? Continuum (Minneap Minn) 2013;19:901-921.
Goldschmidt T, Antel J, König FB, Brück W, Kuhlmann T. Remyelination capacity of the MS brain decreases with disease chronicity. Neurology 2009;72:1914-1921.
Albert M, Antel J, Brück W, Stadelmann C. Extensive cortical remyelination in patients with chronic multiple sclerosis. Brain Pathol 2007;17:129-138.
Kuhlmann T, Lingfeld G, Bitsch A, Schuchardt J, Brück W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002;125:2202-2212.
Pfeifenbring S, Bunyan RF, Metz I, et al. Extensive acute axonal damage in pediatric multiple sclerosis lesions. Ann Neurol 2015;77:655-667.
Bar-Or A. The immunology of multiple sclerosis. Semin Neurol 2008;28:29-45.
Vargas-Lowy D, Kivisäkk P, Gandhi R, et al. Increased Th17 response to myelin peptides in pediatric MS. Clin Immunol 2013;146:176-184.
Balint B, Haas J, Schwarz A, et al. T-cell homeostasis in pediatric multiple sclerosis: old cells in young patients. Neurology 2013;81:784-792.
Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106-2112.
O'Connor KC, McLaughlin KA, De Jager PL, et al. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med 2007;13:211-217.
Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology 2012;78:665-671; discussion 669.
Bar-Or A, Hintzen RQ, Dale RC, Rostasy K, Brück W, Chitnis T. Immunopathophysiology of pediatric CNS inflammatory demyelinating diseases. Neurology 2016;87:S12-19.
